Reversible Pisa syndrome in patients with Parkinson’s disease on dopaminergic therapy
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
The wide variability of dystonic postures manifested in the clinical course of Parkinson’s disease (PD) represents a complicated on-going issue. Several recently published reports of Pisa syndrome (PS) in parkinsonian patients on dopaminergic therapy have described a variable means of onset and clinical course of this truncal dystonia.
To describe PD patients with PS, with the aim of stressing the frequent iatrogenic origin and potential reversibility of this syndrome during the initial stages of its appearance.
Subjects and methods
Eight consecutive PD patients who developed a PS after modifications of antiparkinson therapy were studied. All patients underwent detailed clinical assessment, [123I]FP-CIT-SPECT being performed in three cases. Four patients were videotaped.
All patients developed PS within a variable time-span ranging from 15 days to 3 months after adjustment of treatment. Seven cases of PS were manifested following an increase and one a decrease of dopaminergic treatment. A marked reversal of dystonia was produced in the first seven patients by the withdrawal or dose decrease of dopaminergic PS priming drug, and in the eighth patient an increase of dopaminergic therapy was necessary.
In our opinion, the recognition of reversibility of PS during the initial stages of its appearance may be of considerable clinical importance. Indeed, it may facilitate the rapid withdrawal or reintroduction of dopaminergic treatment, thus avoiding an initial veering towards the subchronic variant and, subsequently into a chronic irreversible variant.
- Ekbom K, Lindholm H, Ljungberg L (1972) New dystonic syndrome associated with butyrophenone therapy. Z Neurol 202:94–103 CrossRef
- Suzuki T, Matsuzaka H (2002) Druginduced Pisa syndrome (Pleurothotonus) epidemiology and management. CNS Drugs 16(3):165–174 CrossRef
- Patel S, Tariot PN, Hamill RW (1991) Pisa syndrome without neuroleptic exposure in a patient with dementia of the Alzheimer Type. J Geriatr Psychiatry Neurol 4:48–51 CrossRef
- Colosimo C (1998) Pisa syndrome in a patient with multiple system atrophy. Mov Disord 13:607–609 CrossRef
- Stubner S, Padberg F, Grohmann R, et al. (2000) Pisa syndrome (pleurothotonus): report of a multicenter drug safety surveillance project. J Clin Psychiatry 61(8):569–574
- Bhattacharya KF, Giannakikou I, Munroe N, et al. (2000) Primary anticholinergic- responsive Pisa syndrome. Mov Disord 15:1285–1286 CrossRef
- Villarejo A, Camacho A, Garcia-Ramos R, Moreno T, Penas M, Juntas R, Ruiz J (2003) Cholinergic-dopaminergic imbalance in Pisa syndrome. Clinical Neuropharmacology 26:119–121 CrossRef
- Cannas A, Solla P, Floris GL, et al. (2005) Reversible Pisa syndrome in Parkinson’s disease during dopaminergic treatment with Pergolide: a case report. Clin Neuropharm 28(5):252 CrossRef
- Garbarin M, Antonini A, Moretto G, et al. (2006) Pisa syndrome without neuroleptic exposure in a patient with Parkinson’s disease: case report. Mov Disord 21(2):270–273 CrossRef
- Yokochi F (2006) Lateral flexion in Parkinson’s disease and Pisa syndrome. J Neurol 253(Suppl 7):VII17–VII20 CrossRef
- Kim JS, Park JW, Chung SW, Kim YI, Kim HT, Lee KS (2007) Pisa syndrome as a motor complication of Parkinson’s disease. Parkinsonism Relat Disord 13(2):126–128 CrossRef
- Duvoisin RC, Marsden CD (1976) Note on the scoliosis of Parkinsonism. J Neurol Neurosurg Psychiatry 38(8):787–793 CrossRef
- Herrera-Marschitz M, Utsumi H, Ungerstedt U (1990) Scoliosis in rats with experimentally-induced hemiparkinsonism ¸dipendence upon striatal dopamine denervation. J. Neurol Neurosurg Psychiatry 53:39–43 CrossRef
- Jankovic J, Tintner R (2001) Dystonia and parkinsonism. Parkinsonism Relat Disord 8:109–121 CrossRef
- Djaldetti R, Hellmann M, Malamed E (2004) Bent knees and tiptoeing: late manifestations of end-stage Parkinson’s disease. Mov Disord 19:1325–1328 CrossRef
- Azher SN, Jankovic J (2005) Camptocormia, pathogenesis, classification, and response to therapy. Neurology 65:355–359 CrossRef
- Jancovic J (2005) Motor fluctuations and dyskinesias in Parkinson’s disease: clinical manifestations. Mov Disorders 20(Suppl 11):S11–S16 CrossRef
- Harada K (2006) Pisa syndrome without neuroleptic exposure in a patient with Parkinson’s disease: A case report. Mov Disord 21(12):2264 CrossRef
- Bruneau MA, Stip E (1999) Metronome or alternating Pisa sindrome: a form of tardive distonia under clozapine treatment. Int Clin Psychopharmacol 13:229–232 CrossRef
- Schwarting RK, Huston JP (1996) The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments. Prog Neurobiol 50:275–331 CrossRef
- Reversible Pisa syndrome in patients with Parkinson’s disease on dopaminergic therapy
Journal of Neurology
Volume 256, Issue 3 , pp 390-395
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Pysa syndrome
- Parkinson’s disease
- Dopaminergic therapy
- Industry Sectors
- Author Affiliations
- 1. Institute of Neurology, University of Cagliari, Via Ospedale 46, 09124, Cagliari, Italy
- 2. Nuclear Medicine, Dept. of Medical Science, Policlinico Universitario, University of Cagliari, Cagliari, Italy